186 related articles for article (PubMed ID: 22731114)
1. Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy.
Biron A; Bobin-Dubigeon C; Volteau C; Piroth L; Perré P; Leport C; Prazuck T; Jovelin T; Billard M; Sébille V; Bard JM; Raffi F; Biron C
AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1672-8. PubMed ID: 22731114
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy.
Hansen BR; Petersen J; Haugaard SB; Madsbad S; Obel N; Suzuki Y; Andersen O
HIV Med; 2009 Jul; 10(6):378-87. PubMed ID: 19490178
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
4. Independent predictors of metabolic syndrome in HIV-infected patients.
Alencastro PR; Fuchs SC; Wolff FH; Ikeda ML; Brandão AB; Barcellos NT
AIDS Patient Care STDS; 2011 Nov; 25(11):627-34. PubMed ID: 21936688
[TBL] [Abstract][Full Text] [Related]
5. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia.
Tesfaye DY; Kinde S; Medhin G; Megerssa YC; Tadewos A; Tadesse E; Shimelis T
Diabetes Metab Syndr; 2014; 8(2):102-7. PubMed ID: 24907175
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
Feleke Y; Fekade D; Mezegebu Y
Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
[TBL] [Abstract][Full Text] [Related]
7. The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: results from a prospective study.
Bonfanti P; De Socio GV; Ricci E; Antinori A; Martinelli C; Vichi F; Penco G; Madeddu G; Orofino G; Valsecchi L; Rusconi S; Menzaghi B; Pocaterra D; Quirino T
Biomed Pharmacother; 2012 Jul; 66(5):348-53. PubMed ID: 22705335
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults.
Jantarapakde J; Phanuphak N; Chaturawit C; Pengnonyang S; Mathajittiphan P; Takamtha P; Dungjun N; Pinyakorn S; Pima W; Prasithsirikul W; Phanuphak P
AIDS Patient Care STDS; 2014 Jul; 28(7):331-40. PubMed ID: 24914459
[TBL] [Abstract][Full Text] [Related]
9. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
[TBL] [Abstract][Full Text] [Related]
10. Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy.
Palacios R; Santos J; González M; Ruiz J; Márquez M
Int J STD AIDS; 2007 Mar; 18(3):184-7. PubMed ID: 17362552
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
12. The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART.
Jevtović Dj; Ranin J; Salemović D; Pesić I; Dragović G; Zerjav S; Djurković-Djaković O
Biomed Pharmacother; 2008 Jan; 62(1):21-5. PubMed ID: 17223307
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
14. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
[TBL] [Abstract][Full Text] [Related]
17. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
[TBL] [Abstract][Full Text] [Related]
18. Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients.
Badiou S; Thiebaut R; Aurillac-Lavignolle V; Dabis F; Laporte F; Cristol JP; Mercie P;
J Infect; 2008 Jul; 57(1):47-54. PubMed ID: 18554723
[TBL] [Abstract][Full Text] [Related]
19. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
[TBL] [Abstract][Full Text] [Related]
20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
